Skip to main content
Premium Trial:

Request an Annual Quote

Senomyx Chairman, CSO Steps Down, New Appointments Made

NEW YORK, May 22 – Senomyx said Tuesday that it had appointed Paul Grayson chairman of the board and promoted Mark Zoller to the position of chief scientific officer, continuing a management reshuffle that has taken place over the past month.

Grayson, who is CEO of the company, and Zoller, who is vice president of research, will be replacing Lubert Stryer in his roles as chairman and CSO.

Stryer is returning to Stanford University following a two-year sabbatical at Senomyx.

"All of us at Senomyx are indebted to Dr. Stryer for his overwhelming contributions to the company," Grayson said in a statement. "His work included not only founding the company but also providing vision and leadership.”

Grayson was also a founder of Senomyx, a La Jolla, Calif.-based developer of flavor and fragrance molecules designed to be used in consumer products.

Earlier this month, Senomyx announced that Saiid Zarrabian, who resigned as chief operating officer at Pharmacopeia in December, had been appointed president and COO of Senomyx, replacing Grayson in his previous role as president.

The Scan

Another Resignation

According to the Wall Street Journal, a third advisory panel member has resigned following the US Food and Drug Administration's approval of an Alzheimer's disease drug.

Novavax Finds Its Vaccine Effective

Reuters reports Novavax's SARS-CoV-2 vaccine is more than 90 percent effective in preventing COVID-19.

Can't Be Used

The US Food and Drug Administration says millions of vaccine doses made at an embattled manufacturing facility cannot be used, the New York Times reports.

PLOS Papers on Frozen Shoulder GWAS, Epstein-Barr Effects on Immune Cell Epigenetics, More

In PLOS this week: genome-wide association study of frozen shoulder, epigenetic patterns of Epstein-Barr-infected B lymphocyte cells, and more.